Alto Neuroscience, Inc. Common Stock, Capital Shares Reserved for Future Issuance
Alto Neuroscience, Inc. (ANRO) had Common Stock, Capital Shares Reserved for Future Issuance of 15.80 million shares as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:CommonStockCapitalSharesReservedForFutureIssuance · last filed 2026-08-12
- 2026-06-30: Common Stock, Capital Shares Reserved for Future Issuance 15.80M shares.
- 2026-03-31: Common Stock, Capital Shares Reserved for Future Issuance 15.85M shares.
- 2025-12-31: Common Stock, Capital Shares Reserved for Future Issuance 11.15M shares.
- 2025-09-30: Common Stock, Capital Shares Reserved for Future Issuance 6.14M shares.
| Period end | Common Stock, Capital Shares Reserved for Future Issuance |
|---|---|
| 2026-06-30 | 15.80M shares 10-Q · filed 2026-08-12 |
| 2026-03-31 | 15.85M shares 10-Q · filed 2026-05-13 |
| 2025-12-31 | 11.15M shares 10-Q · filed 2026-08-12 |
| 2025-09-30 | 6.14M shares 10-Q · filed 2025-11-12 |
| 2025-06-30 | 6.29M shares 10-Q · filed 2025-08-13 |
| 2025-03-31 | 6.34M shares 10-Q · filed 2025-05-14 |
| 2024-12-31 | 5.14M shares 10-K · filed 2026-03-16 |
| 2024-09-30 | 5.26M shares 10-Q · filed 2024-11-12 |
| 2024-06-30 | 5.30M shares 10-Q · filed 2024-08-13 |
| 2024-03-31 | 5.38M shares 10-Q · filed 2024-05-14 |
| 2023-12-31 | 17.63M shares 10-K · filed 2025-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |